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Overline: Fragile X Syndrome 
 
One sentence summary: Brief, early treatments with lovastatin provides long-lasting rescue 
of associative memory deficits in a rat model of Fragile X. 
 
Abstract 
Fragile X Syndrome (FXS) is one of the most common monogenic forms of autism and 
intellectual disability.  Preclinical studies in animal models have highlighted potential of 
pharmaceutical intervention strategies for alleviating the symptoms of FXS.  However, whether 
treatment strategies can be tailored to the developmental time-window that defines the 
emergence of a particular phenotype is unknown.  Similarly, whether a brief, early intervention 
can have long-lasting beneficial effects, even after treatment cessation, is not known. To 
address these questions, we first examined the developmental profile for the acquisition of 
associative learning in a rat model of FXS generated on a Long Evans Hooded background. 
Associative memory was tested using a range of behavioral paradigms that rely on an animals' 
innate tendency to explore novelty.   Fmr1 knockout (KO) rats showed a developmental delay 
in their acquisition of object place recognition but no difference in the acquisition of object or 
object-context recognition relative to their littermate controls.  Furthermore, Fmr1 KO animals 
could not identify novelty in the object-place-context recognition paradigm at any age tested 
(up to 23 weeks of age). Treatment of Fmr1 KO rats with lovastatin between 5 and 9 weeks of 
age, during the normal developmental period this associative memory capability is established, 
prevents the emergence of deficits but has no effect in wildtype animals. Moreover, we observe 
no regression of cognitive performance in the FXS rats over several months post-treatment. 
This restoration of the normal developmental trajectory of cognitive function is associated with 
the sustained rescue of both synaptic plasticity and altered protein synthesis. The findings 
provide proof-of-concept that the impaired emergence of the cognitive repertoire in 
neurodevelopmental disorders may be prevented by brief, early pharmacological intervention. 
 
 
Introduction 
Fragile X Syndrome (FXS) is a major heritable cause of intellectual disability (ID) and one of 
the most common single gene causes of autism spectrum disorder (ASD), with 30-50% of boys 
clinically diagnosed with ASD (28814540). It affects approximately 1:4,000 boys and 1:6-
8,000 girls.  FXS has numerous co-occurring conditions including anxiety disorders, sensory 
hypersensitivity and seizures (28814540).  FXS is usually diagnosed around 3 years of age as 
a result of a delay in language development (2).  However, early diagnosis through genetic 
screening suggests early symptom development in agreement with data from cellular 
phenotypes in rodent models (2-4). FXS is typically caused by an expansions of a trinucleotide 
repeat (CGG) in the promoter region of the gene that leads to silencing of the gene and no 
protein expression (5), although de novo mutations that are predicted to alter protein function 
also cause FXS (6, 7). 
There is abundant preclinical evidence that an array of functional impairments in FXS arise 
from a disruption of cellular biochemistry and physiology that is correctable with 
pharmacological interventions (for reviews see, 2; 8-10).  Furthermore, based on knowledge 
of critical periods in sensory system development and language acquisition (11, 12), it has 
been suggested that therapeutic success would be improved by starting treatments early, 
before major symptoms develop (13).  Further, it is not known whether effective treatments 
would need to be maintained throughout life.   
 
Numerous clinical trials have taken place for FXS including the development of novel 
compounds as well as drug repurposing (14). There are numerous advantages of drug 
repurposing in the treatment of disease, including speed of translation and cost implications 
associated with new drug development (15). When assessing the feasibility of initiating chronic 
treatments in infancy, an obvious concern is safety.  For these reasons, there has been interest 
in the possibility of repurposing drugs with a known safety profile in children.  Two examples 
of such candidates are arbaclofen, a γ-aminobutyric acid B (GABAB) receptor agonist used for 
the treatment of spasticity in cerebral palsy, and lovastatin, an HMG-CoA reductase inhibitor 
used for the treatment of hypercholesterolemia. These compounds have been shown to correct 
the alterations in synaptic plasticity, neuronal morphology and excitability and behavioral 
alterations in a mouse model of FXS (16, 17).  The precise mechanisms underlying this rescue 
in Fmr1 knockout (KO) mice is not known; however, increasing GABAB activation with 
arbaclofen alters the excitability of neurons and reduces presynaptic release of glutamate 
leading to a reduction in postsynaptic glutamate receptor activation, including the metabotropic 
glutamate receptor 5 (mGluR5) (18); two key cellular processes thought to underlie FXS 
pathophysiology (9).  Lovastatin regulates the membrane association of Ras and subsequently 
mildly reduces the downstream activation of the extracellular signal-regulated kinases 1/2 
(ERK1/2) (17). A recent human study evaluating the effects of arbaclofen in child and 
adolescent with FXS suggested that age is indeed a critical variable in determining the effect 
of the treatment; Arbaclofen had therapeutic effects in children that were lost in 
adolescent/adults with FXS (19). Phase 1 clinical trials with lovastatin in FXS were promising 
(20) and a follow up studies have not been reported yet (NCT02680379, NCT02998151, 
NCT02642653).  The combined age range in these trials are 8-55 years of age. 
 
As noted above, a key question for the potential treatment of FXS is the age at which treatment 
should begin to maximize effectiveness. In this study, we tested the hypothesis that lovastatin 
treatment restricted to early development could permanently prevent impairments in cognitive 
function in an animal model of FXS.  We chose lovastatin as it can be orally administered in 
food, it has been shown to ameliorate circuit deficits in Fmr1 KO mice and it has a known 
safety profile in children (17).  
 
Key to addressing this question is knowledge of the development of cognitive abilities in 
animal models. Robust behavioral paradigms independent from reward-based learning that can 
be used repeatedly in the same animals are therefore required.  Therefore, to assess cognition 
across juvenile development in rats, we utilized a battery of spontaneous object exploration 
“novelty preference” tasks. These tasks are based on rodents’ innate preference to explore 
novel over familiar stimuli in their environment (21), and can be used to infer memory for the 
familiar stimulus (22). The four task variants used in the current study test the ability to 
discriminate between novel and familiar objects (object recognition, OR; 22), novel and 
familiar configurations of objects and local contextual cues within the testing box (object-
context recognition, OCR; 23, 24), novel and familiar configurations of objects and their spatial 
locations within the testing box (object-place recognition, OPR; 25) or novel and familiar 
configurations of objects, their spatial locations and the local context (object-place-context 
recognition, OPCR; 25). These tasks were chosen for several reasons. First, we have previously 
reported that whereas adult Fmr1 KO rats show intact short-term recognition (2-5 min) of 
objects (OR), object-context associations (OCR) and object-place associations (OPR), unlike 
their wildtype (WT) littermates they do not show intact short-term memory for object-place-
context configurations in the OPCR task (26). Therefore, we could assess whether treatment 
during juvenile development would ameliorate the deficits in OPC memory in Fmr1 KO rats. 
Second, the tasks are based on spontaneous behavior, and do not depend on acquisition of task 
rules and stimulus-reward contingencies. This means that the same animal can be tested on 
multiple occasions (with different objects) to assess recognition memory at different ages. 
Third, the spontaneous exploration protocol has been used successfully in juvenile rats to 
characterize the ontogeny of recognition memory abilities in rats. These studies have shown 
that object recognition memory emerges before postnatal day 17 in the LEH rat (27), whereas 
object-context recognition emerges at around P17 or P26 depending on the types of cues used 
to define context (28). In contrast, object-place recognition (29) and object-place-context 
recognition (30) emerge later during juvenile development.  Finally, short term (2-5 min) 
recognition memory in the four different task variants described above is thought to depend on 
different overlapping brain circuits (31). Whereas the complete circuitry supporting 
recognition memory in each task is not fully resolved, it is generally agreed that the perirhinal 
cortex is required for object recognition (OR), whereas the entorhinal cortex, hippocampus and 
medial prefrontal cortex (mPFC) are not (although there is debate concerning the role of the 
hippocampus at longer retention intervals, and also its normal role in the intact brain) (23-25, 
31-34) . For the version of the OC task described here (in which context is signaled by local 
non-polarizing cues), the postrhinal cortex and lateral entorhinal cortex (LEC) are necessary 
(24, 34, 35). The LEC together with its connections with the mPFC are required for memory 
in the OP task (33, 34), whereas for the OPC task the hippocampus is required, together with 
the LEC and its connections with mPFC (25, 32, 33).  
In this study, we examine the developmental emergence of associative memory using object 
exploration tasks in a new rat model of FXS. We then examine whether deficits in associative 
memory can be prevented by early treatment with lovastatin and whether they persist after 
treatment termination. Finally, we examine whether lovastatin treatment corrects alterations at 
cellular levels in hippocampus and mPFC, two regions known to be involved in the tasks used 
in the study and known to have altered function in FXS (36, 37).   
 
Results 
 
WT LEH rats show distinct developmental trajectories in different spontaneous object 
exploration tasks 
As a first step to determining the emergence of cognitive abilities in rats, we conducted a 
longitudinal study to examine the developmental time-course over which WT LEH rats exhibit 
non-associative and associative recognition memory capabilities by examining their 
performance on a battery of four spontaneous exploration-based tasks from 4 weeks old to 
adulthood. In all tasks, memory is infered based on the amount of time an animal spends 
preferentially exploring the novel object or novelty based on an object's location and/or context 
(Fig. 1A).  At 4-6 weeks old, rats exhibit novelty preference in both the non-associative OR 
task and the associative OCR task (Fig. 1B, C), indicating memory of objects and object-
context associations. Memory was observed at all subsequent ages tested for these tasks. In 
contrast, novelty preference was not observed in the associative OPR and OPCR tasks at 4-6 
weeks of age but was present at 7-9 weeks and at later ages (Fig. 1D, E). This indicates that the 
circuits necessary for these associative memory processes are not fully mature until 7 weeks of 
age. Total exploration time did not differ between time points for any task (Fig. 1B-E). 
 
 
Loss of Fragile X protein (FMRP) leads to selective deficits in object-place and object-
place-context memory in Fmr1 KO rats 
We generated an Fmr1 KO rat line on the outbred LEH strain (Fig. 2A) to determine whether 
the developmental trajectory of associative memory was altered as a result of chronic deletion 
of the Fmr1 gene. In Fmr1 KO LEH rats, no Fmr1 transcripts were detected by reverse 
transcription-PCR (Fig. 2B). This was also confirmed by RNA sequencing. Similarly, no 
protein was detected using either western blotting or immunohistochemistry (Fig. 2C, D) 
confirming the complete absence of FMRP. In agreement with previous findings in the mouse 
(33) and Sprague-Dawley (SD) rats (26), FMRP is expressed throughout postnatal 
development (Fig. 2E).  
  
At a behavioral level, our results showed that adult (3-4 months old) Fmr1 KO rats on the LEH 
background had selective deficits in the OPCR task, but intact novelty preference in the OR, 
OCR and OPR tasks (fig. S1). This agrees with our previous findings in Fmr1 KO SD rats (26), 
indicating that this pattern of cognitive deficits is shared across outbred strains of adult rats.  
Repeated testing during juvenile development (4-23 weeks) revealed an emergence of OR and 
OCR ability in Fmr1 KO LEH rats undistinguishable from that seen in WT animals (Fig. 2F, 
G). In contrast, the ability of Fmr1 KO rats to show significant memory in OPR was delayed 
by 2-4 weeks compared to WT rats (Fig. 2H). As predicted from our findings in adult rats (26) 
(fig. S1), the Fmr1 KO rats did not exhibit object-place-context associative memory on the 
OPCR task at any age (Fig. 2I). For each of the four tasks, the total time exploring objects in 
the sample and test phases did not differ between genotypes across different time points (fig. 
S2), indicating that the deficits were not secondary to changes in motivation or ability to 
explore objects. 
 
Transient treatment with lovastatin restores wildtype-like developmental trajectory of 
object-place and object-place-context memory in Fmr1 KO rats and has sustained effects 
on memory 
Previous studies in the mouse model of FXS have shown that continuous, chronic treatments 
can correct behavioral phenotypes such as hyperactivity in an open field (17, 38), susceptibility 
to audiogenic seizures (16, 17) and impairments in startle response and inhibitory avoidance 
(38). However, the effects of a transient treatment, initiated early in postnatal life on cognitive 
impairments are still mostly unexplored.  We next tested whether a transient administration of 
the drug lovastatin to juvenile rats would correct the cognitive deficits described above. 
Lovastatin was chosen for three reasons. First by inhibiting the ERK signaling pathway (fig. 
S3), lovastatin has been shown to correct the excessive protein synthesis that is a core 
pathophysiology of FXS, and numerous cellular and circuit-based phenotypes associated with 
the loss of FMRP in mice. Second, lovastatin is an FDA approved drug for the treatment of a 
familial form of hypercholesterolaemia (39) and has a known safety profile in children.  Third, 
lovastatin can easily be administered through the diet (17).  
We tested the effect of administering a five-week oral free-feeding laboratory chow protocol, 
with and without lovastatin (100mg/kg), initiated at 4 weeks, prior to the emergence of 
associative recognition in the OPR and OPCR tasks in WT rats (Fig. 3A). Treatment condition 
(lovastatin vs control diet) had no effect on food intake, and weight gain did not differ between 
genotypes or treatment conditions (fig. S4). Moreover, total object exploration time did not 
differ between experimental groups (fig. S5). However, the lovastatin treatment restored the 
normal developmental emergence of OPR and OPCR abilities in Fmr1 KO rats without altering 
that of WT rats (Fig. 3B, C). Indeed, at 7-9 weeks of age both WT and Fmr1 KO animals on 
lovastatin showed similar novelty preference as WT animals on control chow in the OPR and 
OPCR tasks, whereas Fmr1 KO animals on control chow showed no evidence of memory on 
these tasks at that age (Fig. 3D). OR and OCR ability, which are not impaired in the Fmr1 KO 
rats, were not affected by the lovastatin treatment in either genotype (fig. S6). Next, to 
determine whether the ability of Fmr1 KO rats to perform OPCR requires continuous exposure 
to lovastatin, we terminated the treatment at 9 weeks of age and tested the rats again at 14 and 
23 weeks of age.  Treated Fmr1 KO rats maintained their ability to perform the OPCR task 
even at 14 weeks, and also at 23 weeks of age, 5 and 14 weeks after termination of lovastatin 
treatment respectively (Fig. 3E).  Moreover, the animals’ ability to perform the OPR remained 
unaffected following removal of lovastatin (see Fig. 3B). These results suggest that the 
restoration of the developmental trajectory of associative recognition performance by 
lovastatin treatment persists long after treatment termination. 
 
Early, brief lovastatin treatment corrects increased basal protein synthesis levels in Fmr1 
KO hippocampus 15 weeks after drug removal  
 
We next tested whether the same brief lovastatin exposure produced sustained correction of the 
elevated protein synthesis that is known to result from the loss of FMRP (40-42). Since OPCR 
is a hippocampus-dependent task (32) we examined basal protein synthesis in hippocampal 
slices from the rats used in our behavioral study, harvested at 24 weeks of age.  Fmr1 KO rats 
on control diet showed an increase in basal protein synthesis relative to WT rats even at this 
old age.  The temporary lovastatin treatment between 4 and 9 weeks of age corrected basal 
protein synthesis in Fmr1 KO rats without affecting WT rats (Fig. 3F). 
 
Lovastatin prevents the emergence of prefrontal cortex plasticity deficits associated with 
the loss FMRP 
We next tested whether the same regimen of brief early lovastatin treatment could prevent the 
emergence of an age-dependent phenotype in synaptic plasticity associated with the loss of 
FMRP (43). As mPFC connections are required for OPCR (referred to by Chao et al. as object-
context preference task) (33), and Fmr1 KO mice exhibit an age-dependent deficit in long term 
potentiation (LTP) of synaptic responses in this region (43), we assessed LTP in the mPFC of 
Fmr1 KO rats. Our results show that whereas LTP at layer 2 to layer 5 synapses of mPFC is 
not affected by the loss of FMRP at 4-6 weeks of age (Fig. 4A), LTP in Fmr1 KO rats was 
impaired at 10-12 weeks of age (Fig. 4B). Lovastatin treatment from 5 weeks of age prevented 
the emergence of this LTP deficit as measured in 10-12 week-old animals (Fig. 4C).  
 
Finally, lovastatin has previously been shown to rescue the exaggerated mGluR-dependent 
LTD found in mouse hippocampus at 1 month of age (17). To determine whether a similar 
effect on hippocampal LTD was present in our animals, we first examined whether LTD was 
exaggerated at 4-5 weeks and at 9-10 weeks (the age at which lovastatin is terminated in our 
experiments). Although we confirmed that Dihydroxyphenlyglycine (DHPG) induced LTD is 
exaggerated in Fmr1 KO LEH rats at 4-5 weeks of age, no difference was found at 9-10 weeks.  
Therefore, the effects of lovastatin treatment in our paradigm could not be examined. These 
data suggest that the downstream mechanisms supporting mGluR-dependent LTD change 
during postnatal development (fig. S7). 
 
Discussion 
This study sought to test the hypothesis that early and transient therapeutic intervention can 
produce long lasting benefits on cognition in a rat model of FXS. Our results demonstrate that 
early lovastatin treatment for 5 weeks, initiated before the capabilities for object-place and 
object-place-context associations emerge, restored the normal developmental trajectory of 
these cognitive abilities in Fmr1 KO rats.  Furthermore, the ability to perform associative 
recognition in these tasks persisted for at least 14 weeks after the end of treatment.  These 
findings indicate that brief, early treatment not only prevents the emergence of cognitive 
deficits, but also that the beneficial effects on cognition are sustained long after the end of 
treatment, suggesting that lovastatin might rescue the normal development of the neural circuits 
underlying these behaviors, and that FMRP, lacking in these animals, might not be needed for 
their maintenance. Hence, treating rats during an early developmental time window prior to or 
during the development of cognitive abilities had long-lasting effects on cognition.  
Natural history studies of the symptomatology of individuals with neurodevelopmental 
disorders provide valuable insights into the mechanistic basis of the developmental trajectory 
of these disorders. A challenge for animal studies modelling these disorders is to effectively 
capture developmental trajectories, especially for cognitive abilities (44, 45). Ideally this 
requires longitudinal behavioral testing to assess cognitive ability across development in the 
same animal. In this study, we demonstrate distinct developmental trajectories for different 
types of recognition memory in WT Long Evans hooded rats using a battery of four 
spontaneous exploration-based tasks. The ability to exhibit non-associative memory for objects 
and associative object-context memory is apparent by 4-6 weeks of age [consistent with 
previous findings (28)]. In contrast, we find that the ability to exhibit associative object-place 
and object-place-context memory does not emerge until 7 weeks of age [but see (30)].  Whereas 
the Fmr1 KO rats showed intact memory at each time point in the early-developing object and 
object-context tasks, loss of FMRP specifically affected the later-developing cognitive 
abilities, with a delay in the object-place task, and inability to show memory in the object-
place-context task at any age. OPR and OPCR require the coordination of number of intact 
brain circuits including prefrontal cortex (32-34). The observed abnormalities in OPR and 
OPCR are paralleled by an age-dependent deficit in LTP in the prefrontal cortex. This late 
appearance of LTP deficit in Fmr1 KO LEH rats suggests that the role of FMRP in mediating 
this form of plasticity changes over postnatal development.  A similar conclusion can be drawn 
from our finding that mGluR-dependent LTD in CA1 is increased in Fmr1 KO rats at 1 month 
but not 2 months of age.  It will be interesting in future experiments to determine whether the 
targets of FMRP change over this period or whether the mRNAs associated with polyribosomes 
differ (46) (see below).  
The characterization of developmental trajectories of cognitive function in rodent models of 
neurodevelopmental disorders is important, as it provides a temporal framework for designing 
experiments to determine whether potential therapeutic interventions either prevent the 
emergence of deficits or reverse established deficits. Based on this framework we treated 
animals with lovastatin starting at 4 weeks of age and showed that this intervention prevented 
the emergence of cognitive deficits in object-place and object-place-context recognition 
usually seen at 7-9 weeks in Fmr1 KO rats. Furthermore, even after treatment was terminated 
at 9 weeks, these cognitive abilities remained intact for at least another 3 months (the last time-
point tested). This is particularly important, as untreated Fmr1 KO rats were unable to show 
OPC recognition at any age tested. Lovastatin also prevented the emergence of age-dependent 
deficits in FMRP-dependent synaptic plasticity in the prefrontal cortex of Fmr1 KO rats. 
To investigate the mechanisms underlying the effect of lovastatin treatment, we next examined 
basal protein synthesis in the hippocampus. The increase in protein synthesis in rat 
hippocampus at 4 weeks of age (26) persisted until 6 months of age and was normalized by 
transient lovastatin treatment from 4-9 weeks.  This extends previous findings from the mouse 
model of FXS showing that acute lovastatin application to hippocampal slices corrects deficits 
in basal protein synthesis (17) by demonstrating that oral lovastatin administration can reverse 
this deficit once it has appeared.  More importantly, this reversal lasts for 4 months after 
removal of the lovastatin suggesting that transient inhibition of the ERK signalling pathway is 
sufficient to promote a long-term reset of protein synthesis in FXS. This effect appears to be 
inconsistent with the idea that increased protein synthesis in the hippocampus of Fmr1 KO rats 
is a direct consequence of the loss of FMRP binding to their target RNAs (18). An alternative 
explanation is that the increased basal protein synthesis observed in Fmr1 KO hippocampus 
actually reflects a compensatory response to the absence of FMRP, and this is no longer needed 
following appropriate treatment. Such an interpretation would suggest that most of the excess 
signal in the protein synthesis assay arises from translation of mRNAs that are not direct FMRP 
targets, which is supported by our recent study (46), using the Translating Ribosome Affinity 
Purification (TRAP) assay which detects mRNAs associate with ribosomes. We found that 
FMRP target mRNAs were underrepresented in the ribosome bound pool in Fmr1 KO CA1 
hippocampal pyramidal neurons relative to WT controls (46).  Furthermore, Chrm4 mRNA, 
which encodes the muscarinic acetylcholine receptor 4 (M4), showed an increase in ribosome 
association and stimulation of M4 normalized many Fmr1 KO phenotypes. These findings 
suggest that the increase in translation in Fmr1 KO neurons is a compensatory response to the 
deletion of FMRP rather than a direct result, at least at the ages tested in these studies (46). 
Treatment with lovastatin may remove the trigger for these compensatory changes by 
preventing the developmental emergence of the cellular or circuit dysfunction associated with 
the loss of FMRP. Cellular and circuit excitability dysregulation has been shown in a range of 
brain regions and cell types in Fmr1 KO mice (9, 10). Since circuit activity is known to regulate 
early neural development, lovastatin could be exerting its disease-modifying role through its 
regulation of mGluR-dependent neuronal excitability. This hypothesis is supported by our 
previous findings that acute lovastatin application rescues both audiogenic seizures, and 
mGluR-dependent epileptiform activity in acute brain slices in Fmr1 KO mice (17).  
Furthermore, acute lovastatin treatment rescued the increase in mGluR-dependent LTD in CA1 
in Fmr1 KO mice (17). 
It is important to note the limitations of this study that can be explored in the future.  First 
although there was no alteration in weight gain between genotypes or treatment group, we have 
not been able to measure the dose of lovastatin received by each animal.  Furthermore, we have 
not defined whether a critical period exists for effectiveness of lovastatin treatment or defined 
an effective minimal treatment duration and we have focused on associative learning paradigms 
that rely on an animals’ inherent attraction to novelty. Whether the beneficial effects of 
lovastatin can be generalized to other ages and other forms of learning is unknown, but we note 
that previous studies have reported this to be the case (17). Whether these findings will directly 
translate to clinical outcome for individuals with FXS is unknown. However, in this context it 
is important to remember that our treatment regimen was initiated in 1-month old rats.  
Although it is difficult to accurately estimate the corresponding age in humans, it is clear that 
this is much earlier than the majority of FX individuals enrolled in ongoing trials with lovastatin 
(NCT02680379, NCT02998151, NCT02642653). 
In summary, using assays of cognitive ability that rely on an animal’s natural exploratory 
behavior we have been able to demonstrate that early, brief treatment restores the normal 
developmental trajectory of associative memory acquisition that persists well into adulthood.  
This rescue is paralleled by physiological and biochemical rescue in the prefrontal cortex and 
hippocampus, respectively. The findings provide proof-of-concept evidence that Fragile X 
Syndrome, and perhaps neurodevelopmental disorders more generally, may be amenable to 
transient, early intervention to permanently restore normal cognitive developmental 
trajectories.  
 
Materials and Methods 
 
Study design 
The purpose of this study was to test the hypothesis that early therapeutic intervention can 
produce long lasting benefits on cognition in a rat model of FXS. For behavioral studies four 
groups of rats were used: WT control, WT treatment, KO control, KO treatment; N=12 per 
group based on power calculations on published data from the lab (Langston and wood) (Effect 
size=1.34, α=0.05, power=0.85). Littermates were housed in mixed-genotype cages (3-4 rats 
per cage), and cages were randomly assigned to control or treatment conditions [in line with 
the ARRIVE guidelines (47)]. For the protein synthesis experiments sample sizes were chosen 
based on power calculations on published data from the lab (17, 26, 42) (Effect size=2.12, 
α=0.05, power=0.91); WT control, WT treatment, KO control, KO treatment; N=6 per group 
(at least two slices from each rat used to produce the value for each animal) were used for 
metabolic labelling. In the same fashion for in vitro electrophysiology sample sizes were 
chosen based on power calculations on published data from the lab (17, 26, 42) (Effect 
size=1.45, α=0.05, power=0.82); WT control-N=9, WT treatment-N=7, KO control-N=9, KO 
treatment-N=8; (at least two slices from each rat used to produce the value for each animal). 
Experimenters were blind to the genotype and the treatment during both data collection, scoring 
of behavioral data, and data analysis. For behavioral testing, we excluded data from trials in 
which animals showing very low object exploration (less than 5 s of exploration per object or 
15 s total object exploration during the sample phase, or less than 15 s total object exploration 
in the test phase). No effect of genotype was observed on the number of trials excluded due to 
insufficient exploration. Testing was always performed during the light phase of the cycle. All 
animal experiments were approved by the University of Edinburgh veterinary services prior to 
their start and were performed in accordance with the guidelines established by European 
Community Council Directive 2010/63/EU (September 22, 2010) and by the Animal Care 
(Scientific Procedures) Act 1986. 
 
Animals and treatment 
Male LE-Fmr1em1/PWC, hereafter referred to as Fmr1 KO, and WT littermates, bred in-house 
and kept in a 12h/12h light dark cycle with ad libitum access to water and food were used. 
Colony founders were produced by Sigma Advanced Genetic Engineering (SAGE) Labs, using 
Zinc finger nuclease (ZFN)–mediated disruption of Fmr1 (48) with a targeted construct 
containing coding sequence for eGFP; resulting founders did not express FMRP or eGFP. Pups 
were weaned off their dams at postnatal-day 22 (P22) and housed in mixed genotype cages 
with littermates, 3-4 animals per cage. Animals were genotyped by PCR. Ad libitum standard 
laboratory chow was provided until P29 On P29 the diet was changed to either control or 
lovastatin-enriched (100mg/kg) (Bioserv) diet which was restocked and weighed once daily. 
At P64, animals were returned to ad libitum standard laboratory chow until the end of 
experiment (P164). Rats’ weight and consumption per cage was monitored throughout the 
dosing period (P29-P64) to ensure that diet did not have any adverse effects on their growth.  
 
RNA isolation and RT-PCR 
Total hippocampus RNA was isolated from 4-month olds rats (3 WT and 3 Fmr1 KO) using 
RNeasy Lipid Tissue Kit (Qiagen) as per manufacturer’s instructions. 2 µg total RNA was used 
for cDNA synthesis using SuperScriptIII (Invitrogen) with oligo(dT) and random hexamers. 
PCR was performed using GoTaq Green master mix (Promega). Fmr1 primers span exons 1 to 
4 (Fmr1_e1F: CGA GGA AGG ACG AGA AGA TG and Fmr1_e4R: CAC CCT TTA TCA 
TCC TCA C; amplicon 284bp). Primers to GFP (GFP_F: ACG TAA ACG GCC ACA AGT 
TC and GFP_R: ATG CCG TTC TTC TGC TTG TC; amplicon 421bp) and 18S (18S F: GTG 
GAG CGA TTT GTC TGG TT and 18S R: CAA GCT TAT GAC CCG CAC TT; amplicon 
321bp) and cDNA from a GFP transgenic mouse were used as positive controls.  
 
Immunoblotting 
Hippocampus extracts from Fmr1 KO rats and controls (n=3/age for developmental 
expression; n=3/genotype at P14 to verify loss of expression) were prepared in RIPA buffer 
containing protease inhibitors (Complete EDTA-free), immunoblotted using primary 
antibodies raised to the C-terminal half of FMRP (1:5000; AbCAM ab69815), GFP (1:5000; 
AbCAM ab6673) and b-actin (1:10,000; Sigma AC-74) and imaged as previously described in 
(36). 
 
Immunohistochemistry 
Histology was performed as previously described (49). Coronal sections were reacted with an 
antibody raised to the N-terminal half of FMRP (1:1500, Millipore MAB2160). 
 
Spontaneous object exploration tasks 
Apparatus: Animals were tested in a rectangular polycarbonate testing box (76 cm long × 45 
cm wide × 60 cm tall) with removable walls and floor inserts that could conform to two 
contexts. Context 1: white textured wallpaper and wood-effect linoleum floor. Two Dual Lock 
(3M) re-sealable fasteners were attached to the floor 9cm from the box walls at north-east and 
north-west locations, used to keep the two objects firmly attached to the floor in the same 
locations for every trial. Context 2: matt blue painted walls and black rubber textured floor 
insert, with holes cut to gain access to the Dual Lock re-sealable fasteners where the objects 
were attached. The testing box was placed on a table surrounded on 3 sides by a black curtain, 
with one opening at the south side of the box (where subjects were placed). A lamp in the north-
west corner and large high contrast poster on the north-east corner were used as external cues, 
which remained in the same position and orientation throughout experiments. The external 
environment was kept as consistent as possible and a radio on low volume was used to mask 
potentially distracting noises. A variety of objects were used which were between 8x8x8cm 
and 11x11x11cm, non-porous, and easily cleaned. Each object was only used once per animal. 
Objects were cleaned between trials with 70% ethanol solution and unscented baby wipes 
(Huggies). 
 
Handling and habituation: Starting from P21 (a day before weaning), animals were handled 
daily in the animal house and experimental room for 7 days prior to experiments. Task-specific 
habituation was performed in the two days prior to experiments (P26-27) within the 
experimental apparatus box to familiarize the animals to the apparatus and type of objects. On 
P26, the animals were habituated to both context configurations in cage groups (30 minutes per 
context) in the morning, and individually (10 minutes per context) in the afternoon. Between 
exposures to contexts, rats were placed in an opaque holding bucket. On P27, animals were 
individually habituated twice (morning and afternoon both context configurations each time) 
but this time 2 different objects were fixed in the positions they would encounter objects during 
testing (10 minutes per context, with objects). These objects were not used again during testing. 
During the habituation sessions, subjects were left undisturbed to explore.  
 
Testing in spontaneous object exploration tasks: Rats were tested on 4 different object 
exploration tasks (object recognition, object context recognition, object-place recognition and 
object-place-context recognition) over a two-day period, and testing was repeated in the same 
rats at different ages (P28&P29, P35&P36, P42&P43, P49&P50, P56&P57, P63&P64, 
P70&P71, P77&P78, P98-P105, P164&P165). The general procedures for each task were the 
same.  
For each phase of every task, the experimenter prepared the appropriate context configuration 
and attached two cleaned appropriate objects to the appropriate locations within the box using 
the DualLock re-sealable fasteners. Each animal was then removed from the home cage and 
placed in the box facing the south wall of the apparatus. The sample phase(s) and test phase 
were each 3 min long during which animals were free to explore. An overhead black and white 
camera (Panasonic) was used to monitor the exploring rat around the testing box. The video 
signal was fed into a DVD recorder and a computer on the desk of the experimenter which was 
2 m away from the testing box. The computer ran in-house timing software (National 
Instruments, LabView) whereby the press of a key on the computer mouse would activate a 
timer. This was performed manually by the experimenter who observed the behavior of the rat 
via the computer screen and recorded the amount of time the rat was engaged in exploration of 
each object.  After 3 min, the animal was either placed in the opaque holding bucket (30cm 
diameter containing standard bedding) for 2 minutes (after a sample phase) or returned to the 
home cage (after a test phase). Exploration was defined as the animal actively exploring an 
object with its snout within 2 cm of the object and performing actions such as sniffing and 
whisking. Exploration was not scored when animal was not actively exploring object (i.e. 
climbing or resting on an object).  Novel object positions, test phase contexts, context order in 
OCR and OPCR, and objects, were counterbalanced across genotypes, tasks and time points to 
ensure that the final results were as unbiased as possible. 
Object Recognition (OR) 
Object Recognition (OR, Fig. 1A) is a two-phase non-associative recognition task.  In the 
sample phase, two identical objects are available in either context 1 or 2. In the test phase, two 
objects (one identical to the objects from the sample phase and one novel object) are available 
in the same context as the sample phase. This task is used to test whether the animal can detect 
object novelty and discriminate between two non-identical objects. Higher exploration of the 
novel than the familiar object is indicative of memory for the familiar object.  
 
Object-Place Recognition (OPR) 
Object-Place Recognition (OPR, Fig. 1A) is a two-phase associative-recognition task. In the 
sample phase, two non-identical objects are available in either context 1 or 2. In the test phase 
two objects (both identical to one object from the sample phase) are available in the same 
context as in the sample phase. This task is used to test whether an animal can associate a 
specific object with a location in space. Higher exploration of the object that is in a different 
location than it was experienced in the sample phase is indicative of object-place memory.  
 
Object-Context Recognition (OCR) 
Object-Context Recognition (OCR, Fig. 1A) is a three-phase associative-recognition task. In 
sample phase 1, two identical objects are available in either context 1 or 2. In sample phase 2, 
a different pair of identical objects are explored in the other context. In the test phase, two 
objects (one identical to the objects from sample phase 1, and the other identical to the objects 
from sample phase 2) are available in either context 1 or 2. This task is used to test whether an 
animal can associate an object with a surrounding context. Higher exploration of the object 
which is in a different context than it was experienced in the sample phase is indicative of 
object-context memory.  
 Object-Place-Context Recognition (OPCR) 
Object-Place-Context Recognition (OPCR, Fig. 1A) is a three-phase associative-recognition 
task. In sample phase 1, two non-identical objects are available in either context 1 or 2. In 
sample phase 2, objects identical to those in sample phase 1 are available but the objects have 
swapped locations and are in the other context. In the test phase, two identical objects (identical 
to one of the objects in sample phases 1 and 2) are available in one of the two contexts. This 
task is used to test if the animal can associate an object to a location in a specific surrounding 
context (episodic-like memory). Higher exploration of the object which is in different location 
in that context than it was in the sample phase is indicative of object-place-context memory.  
 
In vitro electrophysiology 
mPFC LTP 
Subjects were anaesthetized using isoflurane and decapitated. The brain was quickly dissected 
out and placed in ice-cold (<4°C) modified slicing aCSF solution (in mM: NaCl 86, NaH2PO4 
1.2, KCl 2.5, NaHCO3 25, D-glucose 24, Sucrose 75, CaCl2 0.5, MgCl2 7). 300µm coronal 
slices containing prelimbic mPFC were cut in ice-cold modified slicing aCSF solution using a 
vibratome and transferred to a holding chamber containing warmed recording aCSF solution 
(in mM: 124 NaCl, NaH2PO4 1.2, KCl 2.5, NaHCO3 25, D-glucose 20, CaCl2 2, MgCl2 1) 
where they were maintained at 35°C for 30 mins. Slices were left to recover for a further 30 
mins at room temperature prior to the start of experimentation. 
Slices were then placed in a submerged recording chamber heated to 31°C and perfused with 
pre-warmed carbogenated recording aCSF solution at a rate of 4-5ml/min. A recording 
electrode was placed in layer 5 of the prelimbic mPFC and stimulating electrode was placed in 
layer 2/3. Stimulating and recording electrodes were staggered to prevent direct antidromic 
stimulation. Synaptic responses were evoked every 30 secs using a bipolar nichrome 
stimulating wire attached to a constant current stimulus isolator delivering a 200µs pulse. 
Following acquisition of a 20min stable baseline, LTP was induced using 5x 500ms trains of 
300Hz stimulation at 3 min intervals. Responses were then recorded for 60 min post 
tetanization. 
Signal waveforms were amplified 1000x, low-pass filtered at 4kHz and digitized at 20kHz. 
fEPSP slopes were normalized to baseline values. Magnitude of LTP was calculated from 40-
60min post-tetanus time points. Normalized data were averaged across experimental groups 
and reported as mean ± SE.  
DHPG-induced LTD 
Horizontal hippocampal slices (400 µm) prepared from P21 to P32 animals were incubated in 
oxygenated ACSF at 31°C for 30 min, then stored at room temperature until recording. An 
incision was made through CA3 prior to recording. Slices were continuously perfused in an 
interface chamber with 30 ± 1°C ACSF saturated with 95% O2-5% CO2 at 4–5 ml/min. 
mGluR-LTD was induced using dihydroxyphenylglycine (S-DHPG; 50 µM) for 5 min. LTD 
magnitude was calculated by dividing the average fEPSP slope from 50 to 60 min post-DHPG 
application by the average fEPSP slope during the 20 min baseline before DHPG application. 
 
Metabolic labelling. 
Hippocampal slices were prepared from age-matched male WT and Fmr1 KO rats in an 
interleaved fashion as previously described (17, 26, 42). Briefly, hippocampi were rapidly 
isolated and 500 µm slices prepared from the dorsal half using a Stoelting tissue slicer. Slices 
were recovered for 4 h in 32.5oC ACSF (in mM: 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 
10 dextrose, 1 MgCl2, 2 CaCl2, saturated with 95% O2 and 5% CO2), then incubated for 30 min 
with 25 µM ActD to block transcription. To measure protein synthesis, slices were then 
transferred to fresh ACSF containing 10 µCi/ml 35S-Met/Cys (Perkin Elmer) and incubated for 
30 min.  After labelling, slices were homogenized, and labelled proteins isolated by TCA 
precipitation.  Samples were read with a scintillation counter and subjected to a protein 
concentration assay (Bio-Rad).  Final data were expressed as counts per minute (CPM) per µg 
protein, normalized to the 35S-Met/Cys ACSF used for incubation, and the average 
incorporation of all samples analysed in that experiment (8 samples per experiment, 4 WT and 
4 Fmr1 KO).  All aspects of the experiments were performed blind to genotype. 
 
Statistical analysis. 
For all experiments, the researchers conducting the experiments, and scoring and analyzing the 
data were blinded to the genotype of the rats and to treatment group. For the lovastatin dosing 
experiments, mixed-genotype cages were randomly allocated to lovastatin and control diet 
groups. Statistical analysis was performed using GraphPad (Prism 6.0), SPSS 16.0 software or 
R v.3.4.4 (R Core Team, 2018); scripts were written and run using RStudio 1.0.153 (RStudio 
Team, 2016). Due to missing data because of our exclusion criteria linear mixed effect models 
(LMEs) were fitted to our longitudinal behavioral data using the R package lme4 v1.1-17 (50). 
Animal identity was included in models as a random effect and the variables of interest as fixed 
effects. To evaluate significance of effects using LMEs, the model without the variable of 
interest (a reduced/null model) was compared to the model with the variable of interest using 
a likelihood ratio test.   Where appropriate statistical significance was assessed using either 
two-way ANOVA or three-way ANOVA. Unpaired two sample t-tests followed by Bonferroni 
correction were used to compare differences between groups. One-sample t-tests were used to 
compare discrimination indicesagainst chance (DI=0) controlled for the false discovery rate 
using the Benjamini–Hochberg procedure (51). Rats were used as an experimental unit 
throughout the manuscript. In electrophysiological experiments were multiple slices were used 
from each animal (LTP/LTD experiments, protein synthesis) average value for each animal 
was used in the analysis. Results are presented as mean ± sem. Probabilities of P < 0.05 were 
considered as significant.  
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Figure legends 
Figure 1. WT LEH rats show distinct developmental trajectories in different spontaneous 
object exploration tasks (A). Schematic of the spontaneous object exploration tasks used. S 
= sample phase, T = test phase; Light and dark grey backgrounds denote distinct contexts; 
Orange icons denote novel object/object association. Discrimination index over time for WT 
LEH rats in (B) OR, (C) OCR, (D) OPR and (E) OPCR tasks. Insert B-E Total object 
exploration time during test phase for each task. For all tasks N(4-6)=13, N(7-9)=13, N(>10)=11; * 
p<0.05 difference from chance (Discrimination Index =0) based on one-sample t-tests. p-values 
from one-sample t-tests have been corrected for false discovery rate using the Benjamini–
Hochberg procedure. For details on t, df and p-values for one-sample t-tests see table S1. 
 
 
Figure 2. Loss of FMRP leads to selective deficits in object-place and object-place-context 
memory in Fmr1 KO rats (A) Zinc finger nuclease (ZFN)–mediated disruption of Fmr1. 
Diagrams illustrate the target site for ZFN cleavage, donor DNA sequence including enhanced 
green fluorescent protein (eGFP) and a nuclear localization signal (NLS) flanked by 5’ and 3’ 
homology recombination arms for homology directed repair (HDR), and the resulting targeted 
locus (top); (B) RT-PCR for Fmr1 and eGFP mRNA in WT and Fmr1 KO rats. Lanes 1-3, 
samples from three WT rats; lanes 4-6 samples from three Fmr1 KO rats; lane 7 –RT control 
from one Fmr1 KO rat; lane 8 GFP positive control (bottom left); (C) Western blot of FMRP 
and GFP expression in WT and Fmr1 KO rats. Lanes 1-2 samples from two WT rats; lanes 3-
5 samples from three Fmr1 KO rats; lane 6 positive control for GFP (bottom right). (D) 
Immunohistochemical localization of FMRP in P15 WT and Fmr1 KO rats (top); scale bar: 
500 µm. (E) Western blot analysis of FMRP expression in hippocampus homogenates from 
WT littermates over postnatal development compared with P15 Fmr1 KO rat (bottom). 
Discrimination index at different ages for WT and Fmr1 KO rats in (F) OR, (G) OCR, (H) 
OPR and (I) OPCR task.  For all tasks NWT(4-6)=13, NWT(7-9)=13, NWT(>10)=11, NKO(4-6)=12, 
NKO(7-9)=12, NKO(>10)=11; * p<0.05 difference from chance (Discrimination Index =0) black for 
WT and red for KO; # p<0.05 difference between groups. Linear mixed effect models (LMEs) 
were fitted to the data (for details see tables S7 and S8). p-values from one-sample t-tests and 
post-hoc two-sample t-tests have been controlled for the false discovery rate using the 
Benjamini–Hochberg procedure. For details on t, df and p-values, one-sample and post-hoc 
two-sample t-tests see table S1. 
 
 
Figure 3. Transient treatment with lovastatin restores wildtype-like developmental 
trajectory of object-place and object-place-context memory in Fmr1 KO rats and has 
sustained effects on both memory and cellular pathophysiology (A) Experimental time 
course for longitudinal assessment of cognitive development in WT and Fmr1 KO rats treated 
with lovastatin between week 4 and week 9 of age. Discrimination index at different ages for 
WT and Fmr1 KO rats treated with control or lovastatin diet in (B) OPR and (C) OPCR task. 
(D) Effect of lovastatin treatment on OPR (Left) and OPCR (Right) memory tested at 7-9 weeks 
of age in WT and Fmr1 KO rats. (E) Effect of lovastatin treatment on OPCR memory in WT 
and Fmr1 KO rats tested at 14 and 23 weeks of age. (F) Effect of lovastatin treatment on 
hippocampus basal protein synthesis levels in WT and Fmr1 KO rats measured at 24 weeks of 
age, after behavioral testing was complete. Sample sizes: OPR 4-6 weeks NWTcontrol=13, 
NWTlova=12, NKOcontrol=12, NKOlova=12; OPR 7-9 weeks NWTcontrol=13, NWTlova=12, 
NKOcontrol=12, NKOlova=12; OPR 14 weeks NWTcontrol=10, NWTlova=11, NKOcontrol=11, NKOlova=8; 
OPR 23 weeks NWTcontrol=11, NWTlova=10, NKOcontrol=11, NKOlova=7; OPCR 4-6 weeks 
NWTcontrol=13, NWTlova=12, NKOcontrol=12, NKOlova=12; OPCR 7-9 weeks NWTcontrol=13, 
NWTlova=12, NKOcontrol=12, NKOlova=12; OPCR 14 weeks NWTcontrol=11, NWTlova=11, 
NKOcontrol=11, NKOlova=8; OPCR 23 weeks NWTcontrol=10, NWTlova=10, NKOcontrol=11, NKOlova=8; 
for protein synthesis N=6 for all groups. * p<0.05 difference from chance (Discrimination 
Index =0) black for WT and red for KO; # p<0.05 difference between groups. Linear mixed 
effect models (LMEs) were fitted to the behavioral data (for details see Tables S7 & S9) and 
two-way ANOVA with post-hoc two-sample t-tests was used to analyse effect of lovastatin on 
hippocampal protein synthesis levels (for details see table S6F). p-values from one-sample t-
tests and post-hoc two-sample t-tests have been controlled for the false discovery rate using the 
Benjamini–Hochberg procedure. For details on behavioral data t, df and p-values for one-
sample t-tests see table S3 and for post-hoc two-sample t-tests see table S4.  
  
 
Figure 4. Lovastatin prevents the emergence of plasticity deficits associated with the loss 
FMRP. (A) Left panel: Time course plotting fEPSP slopes normalised to baseline following 
LTP induction in layer 2 to layer 5 synapses in the prelimbic mPFC taken from 4-6 week old 
WT and Fmr1 KO rats. Right panel: Averages of fEPSP slopes normalised to baseline during 
the last 20min of the recording (70-90min). (B) Left panel: Time course plotting fEPSP slopes 
normalised to baseline following LTP induction in layer 2 to layer 5 synapses in the prelimbic 
mPFC taken from 10-12 week old WT and Fmr1 KO rats. Right panel: Averages of fEPSP 
slopes normalised to baseline during the last 20min of the recording (70-90min). (C) Left 
panel: Experimental time course for assessment of effect of lovastatin treatment beginning at 
5 weeks of age on WT and Fmr1 KO plasticity in the prelimbic mPFC. Middle panel: Time 
course plotting averages of fEPSP slopes normalised to baseline following LTP induction in 
layer 2 to layer 5 synapses in prelimbic mPFC slices taken from 10-12 weeks old WT and Fmr1 
KO treated with either control or lovastatin diet.  Right panel: Averages of fEPSP slopes 
normalised to baseline during the last 20min of recordings (70-90 min). Insets: Example traces 
showing synaptic responses during baseline (black trace) and 80-90 min (grey trace), Scale bar 
0.5mV, 5ms. Sample sizes: LTP 4-6 weeks N=6, for WT and KO; LTP 10-12 weeks N=7, for 
WT and KO; for lovastatin effects on LTP NWTcontrol=9, NWTlova=7, NKOcontrol=9, NKOlova=8; 
*p<0.05, **p<0.01 difference between groups; Two-way ANOVA with post-hoc two-sample 
t-tests were used for data analyses (for details see Table S6G and H). p-values for post-hoc 
two-sample t-tests have been controlled for the false discovery rate using the Benjamini–
Hochberg procedure. 
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Figure S1. Adult Fmr1 KO LEH rats exhibit deficits in OPCR. (A) Discrimination index 
of adult WT and Fmr1 KO LEH rats in spontaneous object exploration tasks. (B) Total 
exploration times of adult WT and Fmr1 KO LEH rats in spontaneous object exploration tasks. 
* p<0.05 difference from chance (Discrimination Index =0) from a one sample t-test and # 
p<0.05 difference between groups from two-way ANOVA with post-hoc two-sample t-test, for 
statistical details see table 6A and 6B.  
 
 
 
 
  
 
Figure S2. Time exploring objects during test phase of spontaneous recognition tasks does 
not differ between genotypes. Total object exploration over time of WT and Fmr1 KO rats in 
(A) OR, (B) OCR, (C) OPR and (D) OPCR tasks. Two-way ANOVA was used for statistical 
analysis, for details see table S2. 
 
 
  
Figure S3. Rationale of lovastatin treatment in Fragile X syndrome. Lovastatin has been 
shown to indirectly downregulate the mGluR5 signalling pathway by limiting active Ras. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S4. Lovastatin has negligible effect on the weight gain of rats. (A) Effect of 
lovastatin diet on WT and Fmr1 KO rat body weight over time. (B) Effect of lovastatin diet on 
food consumption over time. Statistical analysis performed with three-way and two-way 
ANOVA, for details see table S6D and S6E. 
 
 
 
 
 
 
 
  
Figure S5. Time exploring objects during test phase of spontaneous recognition tasks does 
not differ between genotypes with or without lovastatin treatment. Total object exploration 
over time of WT and Fmr1 KO rats on control and lovastatin diet in (A) OR, (B) OCR, (C) 
OPR and (D) OPCR tasks. Three-way ANOVA was used for statistical analysis, for details see 
table S5. 
 
 
 
 
 
 
 
  
Figure S6. WT and Fmr1 KO rats perform equally well in OR and OCR tasks throughout 
development with control and lovastatin diet. Discrimination index over time of WT and 
Fmr1 KO rats on control and lovastatin diet in (A) OR and (B) OCR. * p<0.05 difference from 
chance (Discrimination Index =0) from a one sample t-test, for statistical details see table S3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S7. Fmr1 KO LEH rats exhibit age specific increase of group I mGluR-LTD in 
CA1 of the hippocampus. Left panel: Time course plotting averages of fEPSP slopes 
normalised to baseline following LTD induction by 5min, 100µM DHPG wash-on in 
hippocampal slices taken from (A) 4-5 weeks and (B) 9-10 weeks old WT and Fmr1 KO rats. 
Right panels: Averages of fEPSP slopes normalised to baseline at 40-60mins post DHPG wash-
on. Insets: Example traces showing synaptic responses during baseline (solid trace) and 50-60 
min (dotted trace), Scale bar 0.5mV, 25ms. * p < 0.05. Statistical analysis performed with two-
way ANOVA and post-hoc two-sample t-test, for details see table S6C. 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Statistical results from one-sample t-tests and post-hoc two-sample t-test for 
object exploration tasks throughout development in WT and Fmr1 KO rats
 
 
Table 2. Statistical results from two-way ANOVA of exploration times in object 
exploration tasks throughout development in WT and Fmr1 KO rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Statistical results from one-sample t-tests for object exploration tasks 
throughout development in WT and Fmr1 KO rats with or without lovastatin treatment 
 
 
Table S4. Statistical results from post-hoc two-sample t-tests for object exploration 
tasks throughout development in WT and Fmr1 KO rats with or without lovastatin 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S5. Statistical results from two-way ANOVA of exploration times in object 
exploration tasks throughout development in WT and Fmr1 KO rats with or without 
lovastatin treatment
 
 
 
 
 
 
 
 
 
 
 
 
Table S6. Statistical results from adult object exploration tasks, effect of lovastatin on 
food intake/weight gain, hippocampal basal protein synthesis and synaptic plasticity 
data
 
 
 
 
 
Table S7. Linear mixed effects model distribution tests of behavioural data 
 
 
 
 
 
 
 
Table S8. Linear mixed effects modelling results of WT and Fmr1 KO object 
exploration tasks throughout development 
 
 
 
 
 
 
 
 
Table S9. Linear mixed effects modelling results of WT and Fmr1 KO object 
exploration tasks throughout development with or without lovastatin treatment 
 
 
